Elusys Therapeutics

Elusys Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing antibody therapies for the treatment of infectious diseases. ANTHIM® (obiltoxaximab) Injection, the company's monoclonal antibody (mAb) anthrax antitoxin, received market authorization from the U.S. Food and Drug Administration (FDA) in March 2016. In July 2020, Health Canada approved the New Drug Submission (NDS) for ANTHIM for the treatment of inhalational anthrax. ANTHIM has also received marketing authorization in the European Union and the United Kingdom under the trade name Obiltoxaximab SFL.